4basebio (LON:4BB) Trading Up 2% – Here’s What Happened

Shares of 4basebio PLC (LON:4BB) rose 2% during mid-day trading on Tuesday . The company traded as high as GBX 1,150 ($15.40) and last traded at GBX 1,147 ($15.36). Approximately 146 shares changed hands during trading, a decline of 85% from the average daily volume of 978 shares. The stock had previously closed at GBX 1,125 ($15.07).

Analysts Set New Price Targets

Separately, Royal Bank of Canada reiterated an “outperform” rating and issued a GBX 1,600 ($21.43) price objective on shares of 4basebio in a research report on Thursday, March 13th.

4basebio Stock Performance

The stock has a 50-day moving average of GBX 1,136.22 and a 200 day moving average of GBX 1,180.48. The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52. The stock has a market capitalization of £146.93 million, a price-to-earnings ratio of -1,470.51 and a beta of 1.09.

Insider Buying and Selling

In other news, insider Amy Walker acquired 1,151 shares of the stock in a transaction that occurred on Friday, February 28th. The stock was purchased at an average cost of GBX 1,120 ($15.00) per share, for a total transaction of £12,891.20 ($17,264.23). Also, insider Heikki Lanckriet acquired 2,400 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was purchased at an average price of GBX 1,205 ($16.14) per share, with a total value of £28,920 ($38,730.41). Corporate insiders own 68.44% of the company’s stock.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.